Novartis Takes Aim: Galvus Promotions To Target Other Classes, Not Januvia

Novartis' strategy for launching its dipeptidyl peptidase IV inhibitor Galvus will be to position the antidiabetic as an option against other existing therapeutic classes, not head-to-head against Merck's DPP-IV Januvia